Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
PACE Score for daratumumab-treated newly dxd AL amyloidosis pts provides clinically applicable tool for early mortality risk stratification; uses NT-proBNP >5300 pg/mL, age > 75 years, absence of t(11;14), and ECOG PS.”
Title: Predicting Early Mortality in Newly Diagnosed AL Amyloidosis: Development and Validation of the PACE Score for Daratumumab-Treated Patients
Authors: George Mellgard, Abdul-Hamid Bazarbachi, Saurabh Zanwar, Ute Hengenbart, Geethika Bodanapu, Divaya Bhutani, GuiZhen Chen, Anita D’Souza, Angela Dispenzieri, Morie Gertz, Shaji Kumar, Suzanne Lentzsch, Paolo Milani, Eli Muchtar, Giovanni Palladini, Despina Trajanova, Anannya Patwari, Vaishali Sanchorawala, Mohamad Mohty, Shikun Wang, Efstathios Kastritis, Foteini Theodorakakou, Stefan Schönland, Rajshekhar Chakraborty, Andrew Cowan
You can read the Full Article in American Journal of Hematology.
You can find other articles featuring Robert Z. Orlowski on OncoDaily.
